Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-2674

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-2674). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Divalproex Sodium 500mg 70518 2674 01)

Label for Divalproex Sodium delayed-release 500 mg tablet, quantity 1. The label includes the NDC number 70518-2674-01, manufacturer Sun Pharma in Cranbury, NJ, and repackager RemedyRepack Inc. It provides storage instructions and advises seeing the package insert for directions. The label states RX ONLY and includes safety warnings about keeping the medication out of reach of children.*

FDA Label Image

Divalproex Sodium 500mg 70518 2674 02

Label for Divalproex Sodium 500 mg delayed-release tablets, quantity of 30. The label shows the tablet dosage form and strength, directions to see the package insert, storage instructions, manufacturer as Sun Pharma, and repackaging by RemedyRepack Inc. It also includes a QR code and a note to keep medication out of children's reach.*

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium 500 mg delayed-release oral tablets packaging label showing quantity of 100 tablets. The label includes the NDC number 70518-2674-00, manufacturer information as Sun Pharma, Cranbury, NJ, and repackaging by RemedyRepack Inc., Indiana, PA. Storage instructions and a QR code are also visible.*

FDA Label Image

Spl-divalproex-figure-1 (Spl Divalproex Figure 1)

A bar graph titled Figure 1 comparing percentages between placebo (PBO) and divalproex sodium (DVPX) in two studies measuring YMRS and MRS scores. The graph shows higher percentages for DVPX (60% and 58%) versus PBO (26% and 29%) in Study 1 and Study 2, respectively.*

FDA Label Image

Spl-divalproex-figure-2 (Spl Divalproex Figure 2)

A figure presenting a cumulative distribution plot labeled 'Figure 2' illustrating the percentage reduction in CPS (Clinical Parameter Score) rate. The x-axis shows the percentage of patients from 100 to 0, while the y-axis shows percentage reduction from -100% to 100%. Two curves compare DVPX (divalproex sodium) and placebo effects. Annotations on the right indicate 'Improvement' upward and 'Worsening' downward with a 'No Change' line at 0% reduction.*

FDA Label Image

Spl-divalproex-figure-3 (Spl Divalproex Figure 3)

A cumulative distribution plot labeled as Figure 3 showing percent reduction in CPS rate on the vertical axis versus percent of patients on the horizontal axis, comparing high dose (solid line) and low dose (dashed line) groups. Annotations indicate improvement with increased reduction and worsening with negative reduction values.*

FDA Label Image

Spl-divalproex-figure-4 (Spl Divalproex Figure 4)

A bar chart titled 'Figure 4 Mean 4-week Migraine Rates' compares migraine rates between placebo and Divalproex Sodium (DVPX) groups across two separate studies. The y-axis represents migraine rates, ranging from 0 to 6. Bars show lower migraine rates for Divalproex Sodium compared to placebo in both studies.*

FDA Label Image

Spl-divalproex-structure (Spl Divalproex Structure)

Chemical structure of divalproex sodium, showing the molecular arrangement of the compound with valproate ions and sodium ions depicted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.